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Abstract: In patients presenting mucositis, effective sub-gingival debridement is crucial to prevent
peri-implantitis. The aim of this randomized study was to assess the three-month (T1) effects of a
locally delivered liquid desiccant agent with molecular hygroscopic properties, in association with
manual debridement, at sites with peri-implant mucositis. Twenty-three patients presenting at least
one implant with no radiographically detectable bone loss, a pocket probing depth (PPD) ≥ 4 mm,
and bleeding on probing (BOP), were included. At baseline (T0), patients were randomly assigned to
receive the aforementioned desiccant agent before debridement (Test-Group), or a Chlorhexidine
1% disinfectant gel after debridement (Control-Group). Treatments were repeated after seven and
14 days. Peri-implant soft tissue assessment [PPD, BOP, Modified Bleeding Index (mBI), Visible
Plaque Index (VPI), and Modified Plaque Index (mPLI)] and microbial sampling were performed
at T0 and T1. At T1 the Test-Group presented significantly greater reductions for BOP, mBI, VPI,
and mPLI. Concerning the deepest sites of the treated implants, both groups showed statistically
significant reductions for BOP and mBI between T0 and T1. Furthermore, the Test-Group exhibited a
significant decrease in anaerobic bacteria. Despite these valid outcomes, a complete resolution of the
inflammatory conditions was not achieved by any of the groups.
Keywords: peri-implant mucositis; manual debridement; desiccant agent; disinfectant gel; soft
tissues; microbial sampling
1. Introduction
Over the past decades, the utilization of dental implants for oral rehabilitation has achieved
predictable outcomes and high success rates [1].
The main long-term causes of dental implants failure involve the onset of biological complications,
such as mucositis and peri-implantitis, at the peri-implant soft tissue level. While mucositis is defined
as the presence of a reversible inflammatory soft tissue infiltrate, peri-implantitis implicates bone
loss beyond the physiological crestal remodeling [2,3]. Peri-implant mucositis and peri-implantitis
represent an emerging global burden of disease [4–7].
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Bacterial biofilm plays a fundamental role in the occurrence of periodontal and peri-implant
diseases. It has been assumed that peri-implant mucositis is the precursor of peri-implantitis, as
gingivitis for periodontitis. On this basis, the most efficient proposed prevention of peri-implantitis
development is the early resolution of pre-existing peri-implant mucositis [7,8]; its treatment goal
consists in the eradication or significant reduction of the levels of pathogenic microorganisms, in order
to allow proper soft tissue healing.
The effectiveness of scaling and root planing (SRP) alone has been demonstrated for the
management of peri-implant mucositis, and valid clinical improvements can be obtained through
mechanical, ultrasonic, or laser debridement [9,10]. However, traditional non-surgical approaches
have been proved to be efficiently supported by adjunctive therapies, such as antiseptic mouth-rinses,
topical application of chlorhexidine, and locally delivered antibiotics [11–14]. Adjunctive systemic
antibiotic administration showed good results [15], even if prudence has to be considered to avoid the
emergence of bacterial resistance [16].
Nevertheless, the achievement of a healthy and completely inflammation-free peri-implant soft
tissue condition is not an easily attainable therapeutic task [17,18].
New antiseptic agents have recently been introduced to improve the supra and sub-gingival
debridement efficacy. Among them, a new topical desiccant agent with antiseptic properties has
been proposed as an adjunct to mechanical debridement in the non-surgical treatment of chronic
periodontitis [19–22] and the surgical regenerative treatment of peri-implantitis [23]. This desiccant
product consists of a liquid solution, which contains a concentrated blend of sulfonic and sulfuric
acids compounds. Sulfonated aromatics and free sulfates show a strong affinity to bind to the water
present in the biofilm matrix and to quickly detach it, allowing easier destruction and eradication of
the biofilm.
To the best of our knowledge, there are no previous investigations on the potentiality of
this desiccant agent in the non-surgical treatment of peri-implant mucositis. In the light of these
considerations, the aim of this pilot study was to assess the three-month clinical and microbiological
effects of the desiccant solution compared to chlorhexidine, locally delivered in peri-implant sites
affected by mucositis, as an adjunct to supra and sub-gingival manual debridement.
2. Results
2.1. Demographics
Demographics were assessed at baseline. Twenty-three participants attended the study; 12 patients
in the Test-Group received a desiccant liquid with molecular hygroscopic properties (HYBENX®
Oral Tissue decontaminant™, HBX), and 11 patients in the Control-Group received a disinfectant gel
(Chlorhexidine Digluconate Corsodyl™ Dental Gel 1%, CHX). Patients’ mean age was 58.97 ± 10.09 years.
The overall examined implants were 52, 27 in the Test-Group, and 25 in the Control-Group. The total
number of evaluated peri-implant sites was 312, 162 in Test-Group and 150 in the Control-Group. At T0,
no significant differences between groups were found for age, sex, smoking habit, ASA status (American
Society of Anesthesiologists Classification), TPS (Periodontal Supportive Therapy) sessions/year, and
oral home care procedures (Table 1).
2.2. Clinical Outcomes
Soft tissues comparison between groups is presented in Table 2.
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Table 1. Patients and implants characteristics at baseline (T0).
Variable Overall (n) Test Group HBX (n) Control Group CHX (n) p Value
Number of patients 23 12 11 NS 1
Age 2 58.97 (10.09) 60.55 (6.59) 55.92 (14.45) NS
Number of implants 52 27 25 NS
Sex
Implants placed in Male 27 16 11 NS
Implants placed in Female 25 11 14
Smoking habit
Implants placed in Non-Smokers 45 23 22 NS
Implants placed in Smokers 7 4 3
ASA status
Implants placed in ASA 1 patients 32 18 14 NS
Implants placed in ASA 2 patients 20 9 11
Number of TPS 3 sessions /year
= 1/Year 15 7 8 NS
> 1/Year 37 20 17
Interproximal oral hygiene
No 21 12 9 NS
Yes 31 15 16
1 NS: no statistically significant differences between groups. 2 Age is presented as mean (± standard deviation); 3
TPS: Periodontal supportive therapy.
Table 2. Soft tissues assessment for Test-Group (HBX) and Control-Group (CHX) throughout the
three-month observation interval (from T0 to T1), at all six sites/implant (HBX-Group, n = 162;
CHX-Group, n = 150) and at the Qualifying site/implant (HBX-Group, n = 27; CHX-Group, n = 25).
PPD All Sites/Implant(n = 162)
All Sites/Implant
(n = 150) p Value
Qualifying
Site/Implant
(n = 27)
Qualifying
Site/Implant
(n = 25)
p Value
Observation
Interval HBX Group CHX Group HBX Group CHX Group
T0 (Day 0) 3.70 (0.83) 3.78 (0.81) NS 1 4.85 (0.99) 5.64 (1.50) NS
T1 (Day 90) 3.29 (0.72) 3.55 (0.83) NS 4.37 (1.04) 5.14 (1.61) NS
p value NS NS NS NS
mBI All Sites/Implant(n = 162)
All Sites/Implant
(n = 150) p Value
Qualifying
Site/Implant
(n = 27)
Qualifying
Site/Implant
(n = 25)
p Value
Observation
Interval HBX Group CHX Group HBX Group CHX Group
T0 (Day 0) 1.53 (0.55) 1.53 (0.59) NS 2.67 (0.48) 2.43 (0.51) NS
T1 (Day 90) 0.43 (0.34) 0.93 (0.51) NS 1.48 (0.70) 1.57 (0.65) NS
p value <0.05 * NS <0.05 * <0.05 *
BOP All Sites/Implant(n = 162)
All Sites/Implant
(n = 150) p Value
Qualifying
Site/Implant
(n = 27)
Qualifying
Site/Implant
(n = 25)
p Value
Observation
Interval HBX Group CHX Group HBX Group CHX Group
T0 (Day 0) 75.92% 68.66% NS 100% 100% NS
T1 (Day 90) 42.23% 52.57% NS 42.78% 57.63% NS
p value <0.05 * NS <0.05 * <0.05 *
mPLI All Sites/Implant(n = 162)
All Sites/Implant
(n = 150) p Value
Qualifying
Site/Implant
(n = 27)
Qualifying
Site/Implant
(n = 25)
p Value
Observation
Interval HBX Group CHX Group HBX Group CHX Group
T0 (Day 0) 0.38 (0.46) 0.75 (0.68) NS 0.67 (0.43) 1.21 (1.05) NS
T1 (Day 90) 0.09 (0.20) 0.39 (0.36) <0.05 * 0.26 (0.53) 1.14 (0.86) <0.05 *
p value <0.05 * NS NS NS
VPI All Sites/Implant(n = 162)
All Sites/Implant
(n = 150) p Value
Qualifying
Site/Implant
(n = 27)
Qualifying
Site/Implant
(n = 25)
p Value
Observation
Interval HBX Group CHX Group HBX Group CHX Group
T0 (Day 0) 31.48% 54.76% NS 44.54% 29.01% NS
T1 (Day 90) 8.64% 26.19% <0.05 * 7.43% 10.74% NS
p value <0.05 * <0.05 * <0.05 * NS
Values are presented as mean (± standard deviation); 1 NS: no statistically significant differences between groups; *
Statistically significant differences between groups/observation times. PPD: pocket probing depth (in mm); mBI:
modified bleeding index; BOP: bleeding on probing; mPLI: modified plaque index; VPI: visible plaque index; T0
(Day 0): baseline; T1 (Day 90): three-month follow-up.
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At baseline, no statistical differences between groups were found for overall peri-implant plaque
accumulation and soft tissue inflammatory signs.
At the three-month evaluation, plaque indexes were reduced in both groups, and significantly
lower (p < 0.05) overall VPI and mPLI values were characterized in the Test-Group compared to the
Control-Group. Statistically lower mPLI was also found for Qualifying sites at day 90 in the Test-Group
compared to the Control-Group.
From baseline to follow-up, overall bleeding indexes decreased in both groups. BOP varied from
75.92% to 42.23% and mBI from 1.53 to 0.43 in the Test-Group; BOP varied from 68.66% to 52.57%
and mBI from 1.53 to 0.93 in the Control-Group. Intra-group examinations revealed that, from T0
to T1, reductions were greater and significantly different (p < 0.05) in the Test-Group compared to
the Control-Group.
At the Qualifying sites level, BOP reduction was 57.22% in the Test-Group and 42.37% in the
Control-Group; mBI variations of 1.19 and 0.86 were found for the Test-Group and the Control-Group,
respectively. Intra-group examinations showed statistically significant reductions from T0 to
T1 for BOP and mBI in both groups. Even if the Test-Group presented greater BOP and mBI
reductions, the inter-group analysis failed to find any significant differences between the groups at
three-month follow-up.
At baseline, there was no statistical difference in the average PPD between groups for overall
implants (Test-Group: 3.70 ± 0.83 mm; Control-Group: 3.78 ± 0.81 mm), and for Qualifying sites
(Test-Group: 4.85 ± 0.99 mm; Control-Group: 5.64 ± 1.50 mm). Even if the mean PPD decreased after
three months, the variations were not statistically and clinically significant for both groups.
2.3. Microbiological Results
2.3.1. Bacterial Count Evaluation
In the Control-Group, the comparison of microbial count, expressed as CFU/mg of plaque
(colony-forming units per mg of plaque), between baseline and the three-month recall-appointment,
showed a substantial decrease for all the bacteria searched, from 8.75 × 105 to 1.90 × 105 (mean
value) for aerobic bacteria, and from 4.45 × 105 to 1.51 × 105 (mean value) for anaerobic bacteria
(Figure 1). Also with regard to the Test-Group, a marked decrease in the microbial count was observed,
from 4.07 × 106 to 2.96 × 105 (mean value) for aerobic bacteria, and from 1.45 × 106 to 8.86 × 104
(mean value) for anaerobic bacteria (Figure 2).
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Figure 1. Total microbial count for Control-Group (CHX) between baseline (T0) and three-month
follow-up (T1), for aerobic and anaerobic bacteria, respectively.
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Figure 2. Total microbial count for Test-Group (HBX) between baseline (T0) and three-month follow-up
(T1), for aerobic and anaerobic bacteria, respectively.
2.3.2. Molecular Biology—Multiplex PCR (Polymerase Chain Reaction)
Concerning the data obtained with Multiplex PCR, the Control-Group showed a decrease for all
three periodontopathogenic bacteria detected (Prevotella intermedia 12 vs. 9, Porphyromonas gingivalis 17
vs. 14, Aggregatibacter actinomycetemcomitans 13 vs 12). A decrease was observed also in the Test-Group
(P. intermedia 12 vs. 9, P. gingivalis 20 vs. 14), particularly marked for A. actinomycetemcomitans (14 vs. 3).
The Test-Group revealed significantly greater performances in the microbiological analysis
compared to the Control-Group, exhibiting a validated effect on anaerobic bacteria, especially targeted
on A. actinomycetemcomitans.
2.4. Patients’ Degree of Satisfaction
Regarding the overall degree of satisfaction with the treatment, 10% of patients were satisfied
(score 3), 50% were more than satisfied (score 4), and 40% were very satisfied (score 5). In the Test-Group
10%, 40%, and 50% of patients expressed score 3, score 4, and score 5, respectively. In the Control-Group
10%, 60%, and 30% of patients expressed score 3, score 4, and score 5, respectively.
3. Discussion
The biofilm is a complex aggregation of microorganisms in an adhesive and protective hydrated
bio-matrix (comprised of 10–30% of extracellular polymeric substances and 70% water), permeated
by channels to promote the nutrient supply and the distribution of elements and signal molecules.
The exopolysaccharides (EPS) of the external matrix protect bacterial cells, hinder mechanical attempts
at complete biofilm removal during basic therapy, and have been demonstrated to confer increased
valid resistance to disinfectants and topical or systemic antibiotics [24–27].
According to its porous structure and high water content, it has been postulated [19] that the
bio-matrix could lose its integrity once exposed to the topical action of a strong desiccant agent with
hygroscopic properties. As a consequence, the sub-gingival biofilm becomes particularly vulnerable
to mechanical removal procedures. Recent data in the literature [19,20] has shown that hygroscopic
characteristics of the sulfonated compounds present in the desiccant solution improve the effectiveness
of ultrasonic debridement in the initial treatment of chronic periodontitis.
In this prospective study, aimed to evaluate the outcomes of an adjunctive treatment protocol to
manual SRP for the management of peri-implant mucositis, the same desiccant solution demonstrated
greater plaque and bleeding score reductions compared to chlorhexidine gel, even if a strong statistically
significant evidence was not found (probably due to the small sample size).
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From a clinical point of view, our study results appeared to be in line with two previous randomized
clinical trials [13,28], which experimented the topical administration of minocycline microspheres
and chlorhexidine gel as adjunctive procedures to SRP in the treatment of mucositis. The topical
administration of HBX showed to be effective as the administration of minocycline microspheres in
decreasing the percentage of bleeding sites after probing. However, while the use of controlled-release
antibiotics has to be carefully planned [29] (because of the risk of the emergence of resistant bacterial
strains), HBX does not present any of these risks, and repeated administrations in a short span
are possible.
BOP score offers the advantage of comparability with other studies, but it does not allow the
proper determination of differences in inflammation severity [30]. mBI was hence evaluated to better
understand the variations of peri-implant inflammation between groups. After three months, not only
the prevalence of bleeding sites but also the severity of inflammatory signs was remarkably reduced
through the administration of the desiccant solution compared to chlorhexidine gel use.
In addition, limited advantages were obtained from the use of the CHX in association with manual
SRP. Other clinical trials presented similar results in the evaluation of the efficacy of chlorhexidine gel
for the treatment of peri-implant mucositis. Porras et al. [12] did not show any significant benefits
from the use of 0.12% chlorhexidine gel as an adjunct to SRP. Thone-Muhling et al. [31], comparing
treatments of one stage full-mouth scaling with or without chlorhexidine, found significant reductions
in probing depth at implant sites after eight months, with no significant differences between groups.
Another study by Heitz-Mayfield et al. [18] showed that adjunctive chlorhexidine gel application did
not enhance the clinical outcomes compared to mechanical debridement alone, which was effective in
reducing mucositis inflammation, but not sufficient for its complete resolution. Menezes et al. [32],
evaluating the use of 0.12% chlorhexidine as an adjunct to non-surgical basic therapy, observed that
the use of chlorhexidine was not more effective compared to a placebo agent.
CHX presents good antibacterial activity. Nevertheless, bacterial biofilms are strongly resistant
to the action of disinfectants and antibiotics, which do not counter the persistence of high bacterial
loads even after treatment. Anaerobic species, in particular, are organized in a well-protected layer in
deeper pockets (>4 mm) on the rough implant surface. In these cases, an easier detachment of the
biofilm from the tooth/implant surface after manual treatment could, therefore, be ensured by the
dehydrating action of a desiccant agent, which promotes the EPS precipitation and the entire collapse
of the biofilm structure.
The application of a desiccant solution in the present study was effective and not associated with
any adverse events. These findings seem to corroborate a recently published clinical case series by
Pini-Prato et al. [33], in which HBX was used to treat sites affected by peri-implant mucositis and
peri-implantitis; a complete resolution of the inflammatory signs was achieved after three months
without any significant adverse events.
Even if the desiccant solution was shown to be safe and more effective than chlorhexidine gel as
an adjunctive treatment to manual instrumentation, the overall clinical improvement was limited in
both treated groups. In agreement with other authors [18], the results of our study seem to underline
the fact that complete healing of inflamed peri-implant soft tissue is not an easily achievable goal, no
matter what additional measures are associated with the manual instrumentation.
During the clinical trial, improvements in oral hygiene conditions were observed in both groups
of patients. At follow-up examinations, a statistically lower plaque accumulation was found in sites
treated with the desiccant solution compared to the Control-Group. According to another study [19],
which evaluated the outcomes of the desiccant solution on natural dentition, the findings deserve
further studies in order to better explain our results.
The specific role of bacteria in mucositis and peri-implantitis has been discussed in many studies;
periodontal pathogens usually found in partially edentulous patients with a history of periodontal
disease, also isolated from the peri-implant pockets [34] (Aggregatibacter actinomycetemcomitans,
Porphyromonas gingivalis, Prevotella intermedia, Tannerella forsythia, Treponema denticola), represent
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an additional risk factor in enhancing inflammation and bone loss. Recent investigations did not
show a strong association between specific microorganisms and peri-implant diseases or implant
failure, but a shift from predominantly gram-positive non-motile aerobic and facultative anaerobic
microorganisms towards gram-negative motile anaerobic bacteria was observed [35].
Both antiseptic agents examined in our study caused a decrease in the count of aerobic and
anaerobic bacteria, and for all three periodontopathogens detected. Reductions in the Test-Group,
in comparison with the Control-Group, were greater for all the classes of microbiota examined.
Treatment with HBX resulted in a mean value reduction of more than 1 log of both aerobic and obligate
anaerobic bacteria; a reduction of 78% for A. actinomycetemcomitans was also observed in the molecular
biology investigation.
A study by Thöne-Mühling et al. [31] found no significant variation in the total bacterial load after
eight months and a microbial decrease detectable after 24 hours. Heitz-Mayfield et al. [18] analyzed
the proportion of the total DNA counts of orange complex species, finding >30% at one month with an
unexpected decrease in the mean probing depth at three months, compared to an increase in the mean
probing depth at three months if <30%. It can be assumed that changes in the proportions of specific
bacterial species or complexes did not play an important role in the reduction in total bacterial counts
in the treatment of peri-implant mucositis.
The two studies by Renvert et al. [13,14] could not show any significant differences in bacterial
species or group levels at any time point between the two antimicrobial agents tested. In the first
one [13], the mean values of the bacterial load gradually decreased during the observation period.
Furthermore, no statistical significance was evident between the two antimicrobials for any bacteria
and at any time point. The second study [14] showed a similar pattern and confirmed an overall lower
bacterial prevalence and level compared to cases of advanced periodontitis.
4. Materials and Methods
4.1. Study Design
A single-center, single-masked, parallel-groups, randomized clinical and microbiological study
(Figure 3), was conducted between July and October 2018 at the Dentistry and Maxillo-facial Surgery
Clinic, Department of Surgery, Dentistry, Paediatrics and Gynaecology (DIPSCOMI), University of
Verona, Verona, Italy. The experimental protocol (Protocol HX-GL-ITA13, approval date 20/11/2013)
was approved by the Ethical Committee of the University of Verona. The study was registered
on ClinicalTrials.gov (Identifier: NCT03858959). The study followed the CONSORT Statement
recommendations [36].
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The study was conducted in accordance with the Ethical Principles of the 64th World Medical
Association Declaration of Helsinki and was consistent with good clinical practice. All participants
signed a written informed consent.
The subjects were enrolled among the individuals examined through a survey on prevalence
of peri-implant infections (mucositis and peri-implantitis) among plateau-design locking-taper
implants [37] with a three-year follow-up period. Twenty-three patients, aged between 37 and
71 years, met the study criteria.
Inclusion criteria comprehended the presence of at least one implant with a pocket probing depth
(PPD) ≥ 4 mm, bleeding on probing (BOP), or pus on probing and no radiographically detectable
bone loss (Qualifying site). Exclusion criteria were pregnant or lactating females, patients with severe
systemic diseases or with uncontrolled diabetes mellitus, assumption of agents affecting the periodontal
status within one month prior to the study, use of systemic antibiotics within three months prior to the
study, prophylactic antibiotics requirement, peri-implant specific treatments within six months prior to
the study, and allergy to sulfates and its derivatives.
Patients were randomly assigned (using a predefined computer-generated randomization scheme)
to the Test-Group, which received the administration of a desiccant liquid with molecular hygroscopic
properties (HYBENX® Oral Tissue decontaminant™, HBX) before SRP, or to the Control-Group, which
received the administration of a disinfectant gel after SRP (Chlorhexidine Digluconate Corsodyl™ Dental
Gel 1%, CHX).
A computer software (Microsoft Excel) was used to generate the random sequence, which
was defined by even or odd numbers for the Test-Group or for the Control-Group, respectively.
The sequence generation and proper allocation concealment were monitored by a dentist not involved
in the participants’ enrolment. Opaque and sealed envelopes, each containing the secret code and
bearing on the outside only a number, were opened after patients’ recruitment and informed consent
signing so that the investigator involved in the enrolment and treatment could not know in advance
which treatment the next person was allocated.
4.2. Soft Tissues Assessment
The peri-implant soft tissues were assessed using a periodontal probe (Florida Probe; Florida
Probes Company, Gainesville, FL, US), applying a force of mild intensity. The following parameters
were collected at baseline (T0) and at the three-month recall appointment (T1):
- PPD, recorded in mm as the distance between the gingival margin and the base of the
periodontal pocket;
- BOP, recorded as 0 (no bleeding) or 1 (bleeding) after probing for PPD;
- Modified Bleeding Index (mBI), recorded as 0, 1, 2, 3 according to Mombelli et al. [38];
- Visible Plaque Index (VPI), recorded as 0 (no plaque) or 1 (plaque) after probing for PPD;
- Modified Plaque Index (mPLI), recorded as 0, 1, 2, 3 according to Mombelli et al. [38].
Six sites on each implant were explored, three (mesial, central, distal) on the buccal side and
three on the lingual/palatal side. “Qualifying site” was identified as the site with no radiographically
detectable bone loss, and characterized by the deepest PPD and the presence of BOP.
Peri-implant bone levels were measured using digitally scanned intraoral radiographs, performed
with a parallel technique using the Rinn centering devices [39] (Rinn XCP Posterior Aiming Ring-Yellow,
Dentsply, Elgin, IL, USA).
4.3. Microbial Sampling and Analysis
After supra-gingival plaque removal, the deepest site was isolated with sterile cotton rolls in order
to properly collect a plaque sample (1 mg ca), through two paper points inserted and left for 30 sec at
the base of the periodontal pocket.
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Each collected plaque sample was divided into two Eppendorf tubes: one containing 500 µL of
TE buffer (10 mM Tris-HCl, pH 8, 1 mM EDTA) for the molecular investigation by Multiplex PCR and
stored at −80 ◦C until further processing and one containing thioglycolate medium (BD Difco) for
cultural investigations.
4.3.1. Culture Investigation
The samples, before the microbiological procedures, were carefully vortex mixed for 30 sec and
exposed for 30 sec to an ultrasonic cleaner (Branson mod 1210). This treatment was necessary to
achieve the highest disruption and dispersion of bacteria in the sample without interfering with
their culturability and avoiding DNA damaging. The plaque samples in thioglycolate medium, after
appropriate dilutions (10-fold), were immediately plated on Columbia blood agar (5% sheep blood,
BD Difco), in order to evaluate aerobic and facultative bacteria, and on Schaedler KV blood agar (5%
Sheep Blood, kanamycin, and vancomycin BD Difco), to evaluate strict anaerobic bacteria. Plates
were incubated at 37 ◦C for 48 hours under specific conditions; Columbia blood agar plates where
incubated in a 5% CO2 enriched atmosphere, while Schaedler blood agar plates were placed in an
anaerobic chamber (Whitley DG 250 Anaerobic Workstation, Don Whitley Scientific, Shipley, UK) with
an atmosphere composed of 85% nitrogen, 10% hydrogen, and 5% CO2 as previously described [40].
Colonies that appeared were counted and results referred to CFU/mg.
4.3.2. DNA Extraction and Multiplex PCR Condition
Plaque samples stored in TE buffer were used for genomic bacterial DNA extraction. Briefly,
one-hundred microliters of TE samples were used for DNA extraction, using the bacterial gene DNA kit
(Sigma-Aldrich), according to the manufacturer’s instructions. The extracted DNA was stored at−20 ◦C
until the Multiplex PCR was performed. Multiplex PCR for the detection of periodontopathogenic
bacteria Porphyromonas gingivalis, Prevotella intermedia, and Aggregatibacter actinomycetemcomitans was
conducted using primers and conditions previously described [41].
4.4. Study Protocol and Treatment
At baseline (T0), subjects were randomly assigned to the Test-Group or to the Control-Group.
In order to be examined for microbial sampling, peri-implant soft tissue assessment, and radiographic
bone levels. The implants were consequently treated with HBX, before an SRP professional session,
or CHX, after a SRP professional session. The treatment, performed by the same operator, was then
repeated on days 7 and 14.
The HBX protocol (Figures 4–9 show a clinical case example) consisted of [19] product application
into the periodontal pocket (starting from the base) with a delivery syringe, and then saline solution
irrigation after 60 sec to flush-out the product and Teflon-curettes debridement to remove the deposits.
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The CHX protocol consisted of Teflon-curettes debridement to remove the deposits, associated
with a first saline solution irrigation, and product application into the periodontal pocket (starting
from the base) with a delivery syringe.
Data collection of soft tissue and icrobiological counts were repeated at three-month follow-up
(T1), together with the radiographs.
4.5. Test Substances and Administration
Chlorhexidine Digluconate Corsodyl™Dental G l 1% is an anti eptic gel with cationic n ture, effective
against a wide range of Gram-positive and negative bacteria, favorable for plaque control and oral
inflammation prev ntion. HYBENX® Oral Tissue decontaminant™ is a concentra ed aqueous solution of
lfonated aromatics and free s lfates. Once placed onto susceptible organic material, the product
instantly absorbs free and electrostatically bonded water, denaturing the molecular structure of the
organic matter. Biofilm is expected to be especially sensitive to the disruptive action of HBX solution
by virtue of its porous structure and high water content. In the Test-Group of this study, HBX was
administered before the Teflon-curettes debridement and left in contact with the supra and sub-gingival
plaque biofilm for up to 60 sec, then rinsed with water and evacuated [19].
4.6. Patients’ Degree of Satisfaction
At T1, patients were asked to express a personal degree of satisfaction with the completed
treatment, through a numeric scale from 1 to 5 (score 1 = not at all satisfied, score 2 = partly satisfied,
score 3 = satisfied, score 4 = more than satisfied, score 5 = very satisfied).
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4.7. Statistical Analysis
Univariate analysis was performed by assessing normality assumptions for quantitative data
with the Shapiro–Wilk test; mean and standard deviations were reported for continuous data that
followed a normal distribution, otherwise median and interquartile range (iqr) were reported. For
the qualitative data frequencies, the proportions and 95% confidence intervals for proportions were
calculated. Proportions were compared using the χ2 tests. Upon data normality and homoscedasticity
check, mean comparisons were performed. Paired Student’s t-test was performed to compare a single
mean in two different times over data with normal distribution, while the Mann–Whitney’s U test was
carried out. Unpaired Student’s t-test was carried out to compare the means across two different groups
if the data normality was found; otherwise, signed-ranked Wilcoxon test was performed. Significance
level was set at 0.05, and all analyses was carried out using Stata v.13.0 for Macintosh (StataCorp,
College Station, TX, USA).
5. Conclusions
Although both agents in association with manual debridement were demonstrated to be active in
the reduction of peri-implant inflammatory signs and bacterial loads, the desiccant agent was more
effective than chlorhexidine gel.
However, our findings reflect the difficulties in achieving a complete resolution of inflammation in
peri-implant soft tissues. Further investigations with a larger study sample size and longer follow-ups
are necessary to validate our results.
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